Option chain shows key data for Alterity Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alterity Therapeutics.

Alterity Therapeutics (OTC:PRNAF) Stock, Option Chain

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

ALTERITY THERAPEUTICS LTD by Alterity Therapeutics Limited

Alterity Therapeutics Ltd

Alterity Therapeutics (ATHE) announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting ...

Alterity Therapeutics announces new publication on ATH434

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics has unveiled promising data from its bioMUSE study at an internat...

Alterity Therapeutics Unveils New Advances for MSA Tracking

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics has appointed Abby Macnish Niven as the new Company Secretary fol...

Alterity Therapeutics Appoints New Company Secretary

Alterity Therapeutics (ATHE) has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as CFO o...

Alterity Therapeutics appoints Abby Macnish Niven as secretary

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics Ltd. has issued a news release that may include forward-looking s...

Alterity Therapeutics Alerts Investors on Potential Risks

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics has made significant strides in 2024 with its lead drug, ATH434, ...

Alterity Therapeutics Advances in Neurodegenerative Drug Trials

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, s...

Alterity Therapeutics Advances Amid Successful AGM

Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics has completed the final patient visit in its Phase 2 clinical tri...

Alterity Therapeutics Advances with ATH434 Trial Completion

Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, double-blind, placebo-controlled invest...

Alterity Therapeutics completes last patient visit in ATH434-201 trial

Maxim initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $8 price target Published first on TheFly – the ultimate source for ...

Comments

Alterity Therapeutics

Alterity Therapeutics (PRNAF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga